Tom Winnifrith Bearcast: is my old chum Paul Atherley suffering from Islingtonitis, Guardian reading derangement syndrome?
Superdry – shares up on Q1 “better than our initial expectations”… but what does that mean financially?...
The AA & oh-so-clever hedge fund-style shareholders v. oh-so-clever private equity potential business purchasers...
Early this year we showed the Shorted AIM shares at the start of 2020. How's the performance as at the end of June? (those in bold remain from 2019)...
Early this year we showed the Shorted AIM shares at the start of 2020. How's the performance after the first month of the year? (those in bold remain from 2019)...
Previously writing on Motif Bio (MTFB), in November with the shares above 0.46p I concluded that with clear and significant risk both in delivery from a cash shell and in what the current divestment process will deliver, continue to avoid. The shares last closed at 0.24p but are currently slumping to around 0.15p on the back of a “Corporate Update”…
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2018 and thus far in 2019 (by net short position %, those in bold not on the list at the start of 2019) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
Currently AIM and Nasdaq listed Motif Bio (MTFB) argues “Voluntary Delisting from the Nasdaq Capital Market”. Hmmm – what about those Nasdaq ‘deficiency notices’?...
I warned you all in a bearcast last week that the real threat to Motif Bio (MTFB) was that lender Hercules would start to want its money back and that the company’s cash crisis would thus soon become critical. And lo it came to pass.
Hello Share Tasters. I now always add a warning to any piece I do on medical pioneers. Rewards can be huge if a new drug comes on the market, but the licensing authorities have understandably to be very cautious. A share which I commended to your further research a month ago has just suffered a huge disappointment. US regulators have currently rejected the company’s new iclaprim drug…
Hello Share Crashers. Everyone knows that unless we find new antibiotics, the world will be in an awful mess. The bugs that kill us are becoming immune to antibiotics because we have over-used them. What we need are different antibiotics which germs have not had the chance to get used to...
The biotech sector isn’t my usual area for investment, but one such company that I’ve been following the progress of with interest is Motif Bio (MTFB).
Motif Bio (MTFB) is a stock, whose share price jumped from the starting gate in the spring of this year after the IPO, and had essentially never looked back since. The trajectory since the low was made on the daily share chart in April below 30p has been extremely robust.
Search ShareProphets |
Recent Comments |